Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
All forms of epilepsies except absence seizures Clinical selection for Phenobarbitone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
By mouth 60-180mg at night. Child: 5-8mg/kg daily. By 1.V or I.M. 50-200mg repeated after 6 hours when required [max, 600mg daily]. Status epilepticus: 1.V at rate lower than 100mg/min [max. 15mg/kg].All forms of epilepsy except typical absence seizures. By mouth or by I.V injection, neonate, initially 20 mg/kg by slow intravenous injection then 2.55 mg/kg once daily either by slow intravenous injection or by mouth; dose and frequency adjusted according to response. By mouth, Child 1 month12 years initially 11.5 mg/kg twice daily, increased by 2 mg/kg daily as required; usual maintenance dose 2.54 mg/kg once or twice daily; Child 1218 years, 60180 mg once daily.
Exfoliative dermatitis and Stevens-Johnson syndrome; severe respiratory depression, apnea, laryngospasm, bronchospasm, or hypoten-sion may occur with intravenous administration; prolonged barbiturate therapy may result in osteopenia or rickets; barbiturate dependence; ataxia; drowsiness; mental depression; hyperkinesia in children; paradoxical excitement; lethargy; anemia; restless and confusion in elderly.
Store as labelled. Keep out of reach of children.